Protalix Biotherapeutics, Inc.
(NYSE Amex Equities : PLX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
LHLaboratory Corp. of America Holdings
0.69%168.572.4%$98.20m
DGXQuest Diagnostics, Inc.
0.17%104.914.2%$79.40m
SRCLStericycle, Inc.
0.41%65.886.3%$42.90m
SYNHSyneos Health, Inc.
2.30%57.400.0%$19.93m
HCSGHealthcare Services Group, Inc.
0.32%25.316.7%$13.67m
RCMR1 RCM, Inc.
-0.36%12.460.0%$12.10m
AMEHApollo Medical Holdings, Inc.
1.36%17.880.0%$2.93m
NRCNational Research Corp.
-0.53%63.500.0%$1.68m
PLXProtalix Biotherapeutics, Inc.
-6.27%0.295.7%$0.39m
BASIBioanalytical Systems, Inc.
-4.56%4.190.2%$0.20m
IDXGInterpace Diagnostics Group, Inc.
1.48%0.442.4%$0.17m
PMDPsychemedics Corp.
0.90%9.080.7%$0.15m

Company Profile

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.